<DOC>
	<DOCNO>NCT00176280</DOCNO>
	<brief_summary>-Overall study design : A randomized Phase II study patient metastatic RCC Patients receive chemotherapy gemcitabine 5-FU . Prior chemotherapy patient receive combination Leukine alone ( study cohort 1 ) Leukine-dexamethasone ( study cohort 2 ) . -Chemotherapy : gemcitabine 1.0 g/m2 intravenously ( infused vein ) 30 minute Days 7 21 , Folinic acid 200 mg/m2 Days 7-8 21-22 , 5-FU 400 mg/m2 , intravenously ( infused vein ) 30 minute follow 5-FU 600 mg/m2 intravenously ( infused vein ) 24 hour . •Study drug : - Cohort 1 , Leukine , 250 ug/m2 daily ( 8 ) subcutaneously ( skin ) day 1 , 2 , 3 , 4 , 5 15 , 16 , 17 , 18 , 19 ; - Cohort 2 , Leukine , 250 ug/m2 daily ( 8 ) subcutaneously ( skin ) day 1 , 2 , 3 , 4 , 5 , 15 , 16 , 17 , 18 , 19 dexamethasone 12 mg every 12 hour ( 8 8 pm ) orally ( mouth ) day 3 , 4 , 5 , 6 , 7 , 17 , 18 , 19 , 20 , 21 .</brief_summary>
	<brief_title>Randomized Phase 2 Trial Pre-chemotherapy Leukine vs. Leukine-Dexamethasone Combination With Gemzar &amp; 5-FU Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>STUDY SYNOPSIS Objectives : Primary : 1 . Determine response rate overall survival patient metastatic renal cell carcinoma ( RCC ) receive pre-treatment Leukine-dexamethasone v Leukine alone combination gemcitabine-5-FU . 2 . Determine pre-treatment combination Leukine-dexamethasone effective pre-treatment Leukine alone reduce hematopoietic non-hematopoietic toxicity gemcitabine-5-FU patient metastatic RCC . Secondary : 1 . Determine effect combination Leukine-dexamethasone v Leukine alone number function peripheral blood dendritic cell , cytokine level give prior gemcitabine-5-FU patient metastatic RCC . 2 . Determine quality life toxicity treatment patient metastatic RCC receive pre-treatment Leukine-dexamethasone v Leukine alone combination gemcitabine-5-FU . 3 . Determine dose intensity administer treatment group . Study Design : - Overall study design : A randomized Phase II study patient metastatic RCC Patients receive chemotherapy gemcitabine-5-FU . Patients receive prior chemotherapy combination Leukine alone ( Cohort 1 ) Leukine-dexamethasone ( Cohort 2 ) . - Patient eligibility : ) chemotherapy naive patient biopsy proven RCC , b ) PS ( ECOG ) , 0 , 1 , 2 , c ) measurable disease RECIST criterion , ) previous immunotherapy anti-angiogenic therapy allow , e ) adequate bone marrow , renal hepatic function define AGC &gt; 1500 PLC &gt; 100,000 mm3 serum creatinine bilirubin &lt; 1.5 mg/dl . - Chemotherapy : Cohorts 1 2 : Days 7 21 : gemcitabine 1.0 g/m2 intravenously 30 minute ; Days 7-8 21-22 : Folinic acid 200 mg/ m2 , 5-FU 400 mg/ m2 , intravenously 30 minute follow 5-FU 600 mg/ m2 intravenously 24 hour . - Study Drugs : - Cohort 1 , Leukine , 250 ug/m2 daily ( 8 ) subcutaneously day 1 , 2 , 3 , 4 , 5 , 15 , 16 , 17 , 18 , 19 ; - Cohort 2 , Leukine , 250 ug/m2 daily ( 8 ) subcutaneously day 1 , 2 , 3 , 4,5 , 15 , 16 , 17 , 18 , 19 dexamethasone 12 mg every 12 hour ( 8 8 pm ) orally day 3 , 4 , 5,6 , 7 , 17 , 18 , 19 , 20 , 21 . - Evaluations trial : Baseline : history physical examination vital signs/weight , estimation performance status ( PS ) , CAT scan chest , abdomen pelvis , EKG , CBC/differential , urinalysis , complete biochemistry profile ( CMP ) ( 12 component ) quality life assessment . Prior course : interim history , physical examination vital signs/weight , grade toxicity , estimation PS , CMP , CBC/differential . Prior course 3 , 5 , thereafter ( every course ) : CAT scan chest , abdomen , pelvis , tumor response quality life assessment . Each week initiation study ( ie day1 , course 1 ) : CBC/differential , x 3 ( Monday Wednesday Friday ) . Biologic study include assessment dendritic cell number function ( 20 ml blood ) , day 1 7 course 1 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>1 . Patients must histologically prove , metastatic RCC . Patients may either recurrent primary Stage IV unresectable regionally advanced disease . 2 . Previous surgery ( nephrectomy ) , immunotherapy IL2 , IFNa cytokines antiangiogenic therapy allow therapy must complete four week prior entry study . 3 . Previous radiation therapy allow complete least four week prior study entry therapy administer &lt; 25 % bone marrow . 4 . Patients must &gt; 18 year age ( age limit require State Kentucky ) . Women childbearing potential must negative pregnancy test must willing consent use effective contraception treatment reasonable period thereafter . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 5 . Patients must ECOG PS 0,1 2 . 6 . Patients must least one target lesion accord RECIST criterion . Bone metastases , leptomeningeal disease , ascites , pleural pericardial effusion , lymphangitic spread cystic lesion acceptable target lesion . 7 . Patients must expect survival least four month . 8 . Patients must adequate organ marrow function define follow : leukocyte &gt; 3,000/mm3 , absolute neutrophil count &gt; 1,500/mm3 , hemoglobin &gt; 8.0g/dl , platelet &gt; 100,000/mm3 , total bilirubin serum creatinine must &lt; 1.5 mg/dl . Liver transaminases ( SGOT and/or SGPT ) may 2.5 institutional upper limit normal ( ULN ) alkaline phosphatase &lt; ULN alkaline phosphatase may 4 ULN transaminase &lt; ULN . 9 . Patients must ability understand willingness sign write informed consent document . Patients right withdraw study time , without prejudice . 1 . Patients previous history cancer exclude unless curative treatment complete &gt; 5 year prior entry onto study one following : situ carcinoma ( location ) , basal cell carcinoma , nonmetastatic squamous cell carcinoma skin . 2 . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , uncontrolled untreated cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 3 . Patients require non study corticosteroid reason exclude . 4 . Pregnant woman exclude study teratogenic potential 5FU gemcitabine . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Lactating woman also exclude . Post menopausal woman must amenorrheic least 12 month consider nonchildbearing potential . 5 . Patients may receive investigational agent . 6 . Peripheral neuropathy must ≤ grade 1 . 7 . Patients history uncontrolled seizure , central nervous system disorder psychiatric disability judge Investigator significant enough preclude inform consent interfere compliance oral drug intake exclude . 8 . Major surgery within 4 week prior study treatment start , lack complete recovery major surgery . 9 . Participation investigational drug study within 4 week precede treatment start . 10 . Lack physical integrity upper gastrointestinal tract malabsorption syndrome inability swallow tablet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Renal</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>RCC</keyword>
	<keyword>Leukine</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>5 Fluorouracil</keyword>
	<keyword>5 FU</keyword>
	<keyword>Metastatic</keyword>
</DOC>